Journal
CELL DEATH & DISEASE
Volume 12, Issue 3, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41419-021-03540-y
Keywords
-
Categories
Funding
- Ligue contre le Cancer (equipe labellisee)
- Agence National de la Recherche (ANR) - Projets blancs [AMMICa US23/CNRS UMS3655]
- Association pour la recherche sur le cancer (ARC)
- Association Ruban Rose
- Canceropole Ile-de-France
- Chancelerie des universites de Paris (Legs Poix)
- Fondation pour la Recherche Medicale (FRM)
- High-end Foreign Expert Program in China [GDW20171100085]
- Fondation Philanthropia
Ask authors/readers for more resources
The circulating metabolome provides insights into how the organism responds to pathogenic challenges. Alterations in the plasma metabolome of COVID-19 patients varied based on the severity of the disease, with major changes observed in critical patients compared to mild cases. Understanding these metabolic shifts could potentially help in identifying therapeutic targets for COVID-19.
The circulating metabolome provides a snapshot of the physiological state of the organism responding to pathogenic challenges. Here we report alterations in the plasma metabolome reflecting the clinical presentation of COVID-19 patients with mild (ambulatory) diseases, moderate disease (radiologically confirmed pneumonitis, hospitalization and oxygen therapy), and critical disease (in intensive care). This analysis revealed major disease- and stage-associated shifts in the metabolome, meaning that at least 77 metabolites including amino acids, lipids, polyamines and sugars, as well as their derivatives, were altered in critical COVID-19 patient's plasma as compared to mild COVID-19 patients. Among a uniformly moderate cohort of patients who received tocilizumab, only 10 metabolites were different among individuals with a favorable evolution as compared to those who required transfer into the intensive care unit. The elevation of one single metabolite, anthranilic acid, had a poor prognostic value, correlating with the maintenance of high interleukin-10 and -18 levels. Given that products of the kynurenine pathway including anthranilic acid have immunosuppressive properties, we speculate on the therapeutic utility to inhibit the rate-limiting enzymes of this pathway including indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available